top of page

ADVERTISEMENT

Therasage Fall Banner.jpg
Mid slider ad reduced.jpg
MHI Square 2.jpg

ADVERTISEMENT

Our top picks

MAHA Inaugural Ball

EXCLUSIVE COVERAGE

Donald Trump

TRUTH AND TRANSPARENCY

Trump wins 2024 election

RFK JR

Pursuit of Pet Longevity

FUREVER FAITHFUL

ADVERTISEMENT

Shocking Ozempic Side Effect: Aver Reveals Weight-Loss Drug Led To 'Significant Bone Loss'


A celebrity is opening up about the alarming risks of using Ozempic for weight loss.


Singer Avery, 30, revealed that she developed osteoporosis after using Ozempic, a drug originally intended for type 2 diabetes but widely used for weight loss.


"I'm kind of in shock right now because I wasn't expecting this. Ozempic can cause bone density loss and I didn't think that would happen to me because I was only on it for a year," Avery said in an Instagram video.


"I have significant bone loss. I have osteoporosis and osteopenia. That's what happens if you use Ozempic for weight loss and you lose too much weight."


Ozempic, also known as semaglutide, is a GLP-1 receptor agonist that helps regulate blood sugar and suppress appetite. Its weight-loss effects have made it a sought-after prescription for celebrities and people looking to shed pounds quickly.


According to a survey by the Kaiser Family Foundation (KFF), 12% of U.S. adults have used a GLP-1 agonist like Ozempic, with 6% currently taking one for weight loss or diabetes management. Of those using the drug, one in five have been told they were overweight.


Avery’s revelation has raised new concerns over whether Ozempic may contribute to bone health issues such as osteoporosis, a condition that causes bones to become weak and brittle.


Dr. Doug Lucas, an orthopedic surgeon and osteoporosis specialist, confirmed that this condition is being seen more frequently with the growing popularity of GLP-1 drugs. He explains that the drugs make it easier for people to consume less protein and go beyond the calorie intake required by the body.


"The challenge with these drugs is it makes it easier to undereat protein as well as to grossly overshoot your calorie deficit for weight loss," Dr. Lucas explained.


"The good news is Avery absolutely has the ability and the potential to grow her bone density back and I'm happy to help her do that."


Dr. Lucas is featured in Lolli Brands Entertainment's upcoming documentary, "sHEALed," which focuses on the woman's health journey--from birth to post-menopause. The highly-anticipated film is set to premiere on Amazon Prime Video in Summer 2025.


Osteoporosis affects approximately 200 million women worldwide, with its prevalence increasing with age. In the United States, osteoporosis affects around 12.6% of adults aged 50 and older, with a significantly higher prevalence among women (19.6%) compared to men (4.4%), according to the Centers for Disease Control and Prevention (CDC) 2018 data.


While Ozempic is generally considered safe when used under medical supervision, it may come with side effects. Novo Nordisk, the manufacturer of Ozempic, lists gastrointestinal issues as the most commonly reported side effects but does not currently recognize osteoporosis as a known risk.


In the United Kingdom, nearly 3,000 people reported experiencing side effects from weight-loss injections like Ozempic in early 2024, with complaints ranging from severe stomach problems to blurred vision and dizziness, The Sun noted.


Avery has urged the public to be cautious when using the medication for weight loss and to fully understand the potential risks before starting treatment.


Disclaimer:

The information provided here is for entertainment and educational purposes only. It is not intended to substitute medical professional advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Visit the disclaimer link for more details: www.biohackyourself.com/termsanddisclaimers

0 comments

Comments


Therasage Fall Banner.jpg
Mid slider ad reduced.jpg
MHI Square 2.jpg
bottom of page